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Abstract 
The NKG2x/CD94 (x=A, C, E) natural killer cell receptors perform an important role in 
immunosurveillance by binding to HLA-E complexes that exclusively present peptides derived 
from MHC class I leader sequences, thereby monitoring MHC class I expression.  We have 
determined the crystal structure of the NKG2A/CD94/HLA-E complex at 4.4 Å resolution, 
revealing two critical aspects of this interaction.  First, the C-terminal region of the peptide, 
which displays the most variability among class I leader sequences, interacts entirely with CD94, 
the invariant component of these receptors.  Secondly, residues 167-170 of NKG2A/C account 
for the ~6 fold higher affinity of the inhibitory NKG2A/CD94 receptor compared to its activating 
NKG2C/CD94 counterpart.  These residues do not contact HLA-E or peptide directly but instead 
form part of the heterodimer interface with CD94.  An evolutionary analysis across primates 
reveals that while CD94 is evolving under purifying selection, both NKG2A and NKG2C are 
evolving under positive selection.  Specifically, residues at the CD94 interface have evolved 
under positive selection, suggesting that the evolution of these genes is driven by an interaction 
with pathogen-derived ligands.  Consistent with this possibility, we show NKG2C/CD94, but not 
NKG2A/CD94, weakly, but specifically binds to the CMV MHC-homologue UL18.  Thus, the 
evolution of the NKG2x/CD94 family of receptors has likely been shaped both by the need to 
bind the invariant HLA-E ligand and the need to avoid subversion by pathogen-derived decoys.  
 
 
[ 3 ] 
Introduction 
Natural killer (NK) cells complement adaptive T-cell responses by monitoring other cells for the 
normal expression of classical MHC class I proteins, often dysregulated during viral infection and 
neoplastic transformation.  Human NK cells express two major classes of class I-specific 
receptors (1).  The killer inhibitory receptor KIR family, consisting of eleven highly polymorphic 
receptors that utilize two or three tandem Ig-superfamily domains in their ectodomains, bind 
directly to classical MHC molecules.  The NKG2x/CD94 receptors (x=A/B, C, E/H, where A/B 
and E/H are splice variants) contain C-type lectin-like (CTLD) ectodomains and bind to the non-
classical MHC protein HLA-E, which presents peptides derived from the relatively conserved 
leader sequences of classical MHC proteins and HLA-G (2, 3).  
 Although NKG2x/CD94 receptors bind to the common ligand HLA-E, different members 
of the family can transmit opposing signals via their intracellular domains.  NKG2A/CD94 
functions as an inhibitory receptor by signaling through two inhibitory ITIM motifs 
(V/IxYxxL/V), whereas NKG2C/CD94 functions as an activating receptor by associating with the 
DAP12 signaling adapter (Lanier, 1998).  How NK cells integrate multiple opposing signals into 
a single output (kill or tolerate) is not well understood, although it is generally thought that 
inhibitory signals predominate.  Perhaps enabling this dominance, NKG2A/CD94 binds to HLA-
E complexes with affinities consistently six-fold stronger than NKG2C/CD94 (4).  This trend has 
also seen in other NK receptor families with paired stimulatory/inhibitory receptors, including the 
KIR and Ly49 families.  It has been proposed that some activating receptors may have evolved to 
bind pathogen-derived ligands directly, but only one example has been firmly established: the 
recognition of mCMV m157 by murine Ly49H (5, 6). 
 HLA-E is highly homologous to classical MHC proteins but has acquired critical changes 
that restrict the repertoire of peptides it binds to nonamers derived from the leader sequences of 
classical MHC (3, 7-10).  The HLA allele from which the nonamer peptide is derived 
significantly influences the strength of interaction with the NKG2x/CD94 receptor, despite single, 
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conserved substitutions in most cases (3, 4, 8, 11, 12).  The importance of HLA-E in viral 
surveillance is underscored by the fact that it is targeted for subversion by the CMV protein 
gpUL40, which contains the HLA-E peptide sequence VMAPRTLIL within its leader sequence 
(13, 14).  
 Previous studies have not conclusively determined how NKG2x/CD94 receptors 
recognize different HLA-E-restricted peptide, but binding studies have shown that the two most 
critical peptide contact points for huNKG2x/CD94 are positions P5, an invariant Arg, and P8, a 
variable hydrophobic residue in class I leaders (12, 15, 16).  Based on the structure of MICA 
bound to NKG2D, Li and coworkers proposed that NKG2A/CD94 would bind HLA-E with 
CD94 oriented over the α1 helix of HLA-E and C-terminal part of the peptide, and NKG2A over 
the α2 helix (17).  Subsequent binding and mutagenesis studies of HLA-E helices (4, 12, 18) 
provided further support for this orientation, indicating CD94 is likely responsible for reading out 
the C-terminus of the peptide.  The structural basis for affinity differences between NKG2x/CD94 
receptors has also not been conclusively determined, partly because of the high sequence 
similarity between these receptors.  Here we present the crystal structure of a complex between 
NKG2A/CD94 and HLA-E that directly answers these questions and suggests an alternate role 
for the activating NKG2C/CD94 receptor. 
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Results 
Soluble forms of the ectodomains of NKG2A/CD94 and HLA-E were refolded in vitro from 
bacterial inclusion bodies (4).  For crystallization, HLA-E was complexed with the nonamer 
peptide derived from HLA-G (VMAPRTLFL), which binds NKG2x/CD94 with the highest 
affinity of any HLA-E/peptide combination so far tested (4).  Initial phases were determined by 
molecular replacement using previously-determined structures of CD94 (19) and HLA-E (10) as 
search models (Supplementary table 1).  The asymmetric unit (AU) contained two complete 
complexes of NKG2A/CD94–HLA-E.  Despite the low resolution (dmin = 4.4Å), electron density 
was continuous and interpretable throughout one of the two NKG2A molecules (Supplementary 
Figure 1), allowing a de novo chain trace (Figures 1A, 1B and 1C); the maps were of sufficient 
quality to unambiguously assemble complexes and assign approximate contacts (Supplementary 
Figure 1, Figure 1D).  The validity of our modeling, beyond reasonable refinement statistics 
(Supplementary table 1), is demonstrated by consistency with previous binding and modeling 
studies (4, 12, 17, 18) and good agreement between NKG2A/CD94 from our structure and its 
recently determined crystal structure (PDB accession 3BDW, (12)).  The de-novo built NKG2A 
molecules from our structure superimpose with an rmsd of 0.59-0.60 Å with the NKG2A 
molecules from 3BDW.  In addition, the NKG2A/CD94 receptor structure and our complex 
structure superimpose with rmsd’s of 0.76 to 0.86 Å (Figure 1C), resulting in essentially identical 
pseudo-dyad axes relating NKG2A to CD94 (~175°) free or bound to HLA-E.  For our final 
structure, we replaced the de novo-built NKG2A moiety with its actual crystal structure primarily 
to improve the stereochemistry, since the difference in refinement statistics using the de novo 
model or 3BDW was modest.  Despite application of non-crystallographic symmetry (NCS) 
restraints throughout refinement, the orientation of the two NKG2A/CD94 receptors on their 
respective HLA-E ligands differs significantly by ~5°, indicating some flexibility in binding.  We 
also note that the overall orientation of receptor on ligand, ~67° (Fig 1B), is more orthogonal than 
predicted by previous modeling attempts, at ~40° (12). 
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In the receptor, two elements are primarily responsible for the formation of the interface 
between NKG2A and CD94 (Figure 2).  One is formed on the membrane-proximal (N-terminal) 
face of the heterodimer where β-strand 1 (β1) from both NKG2A and CD94 bridge the dimer 
interface and join β-sheet 1 (β1, β2 and β7) of each monomer into an extended β-sheet containing 
a total of six β-strands.. The second region of the heterodimer interface is formed by CD94 
residues 107-111 (sequence: MFSSS) and NKG2A residues 168-171 (sequence: IISP), which are 
just C-terminal to the 2nd α-helix of NKG2A.   
 In the complex, CD94 binds over the α1 helix of HLA-E and unambiguously contributes 
all contacts to the C-terminal portion of the peptide, while NKG2A sits over the over the α2 helix 
(Figure 3A).  The interface between NKG2A/CD94 and HLA-E/peptide buries ~2600 Å2, with 
CD94 accounting for ~1400 Å2 and NKG2A ~1200Å2.  Two stretches of CD94 residues make 
significant contacts with the HLA-E platform: CD94Q112, CD94Q113 and CD94F114, which are 
directly adjacent to the interface with NKG2A; and CD94N160, CD94L162, CD94D163 and CD94E164. 
CD94F114 and CD94L162 bind to a hydrophobic patch that includes HLA-EV76, HLA-EI73 and P8Phe 
of the peptide (Figure 3B).  Other CD94 residues that contribute contacts include CD94N156, 
CD94D158 and CD94N170.  Considering the modest resolution of our structure, with appropriately 
conservative modeling of NKG2A side-chains, it is still clear that NKG2AR137, NKG2AP171, 
NKG2AK199, NKG2AQ212 and NKG2AK217 contact HLA-E residues HLA-ES151, HLA-EE154, HLA-
EH155, HLA-EA158, and HLA-ED162.  CD94Q112 makes the most extensive peptide contacts of any 
CD94 residue by intercalating into the peptide between P5Arg and P8Phe, though clear density for 
the side-chain of P5Arg is absent, making confident assignment of contacts to this residue difficult.  
CD94Q112 is in closest proximity to peptide position P6Thr, interacting with the peptide backbone 
as this side-chain is buried in HLA-E.  CD94N156 and CD94N158 are part of a loop that abuts P8Phe.  
Sullivan and coworkers reported that a CD94N158A mutation actually increased binding to HLA-E 
~three-fold, supporting a direct, main-chain interaction between CD94N158 and P8Phe.   
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 Mapping receptor/ligand interface contacts in our structure is largely consistent with 
previous mutagenesis studies (12, 18), predicting that all residues that, when mutated, decrease 
affinity by ten-fold or more are also direct contacts (HLA-EQ72, HLA-ER75, HLA-EV76, HLA-
EE152, HLA-ED162, CD94Q112, CD94Q114, CD94N160, CD94162, CD94D163, CD94E164; Figure 3C).  
Residues where more modest three- to four-fold affinity decreases are seen when mutated 
(NKG2AQ220, NKG2AR215, HLA-ER65, HLA-ER75, HLA-EE166; CD94D168) do not appear to be 
direct contacts in our analysis.  Several contacts in the complex structure (HLA-EH155, HLA-ED69, 
NKG2AS172) only demonstrated a modest (~two-fold) decrease in affinity when mutated, 
suggesting that these residues do not contribute significantly to ∆G of binding.   
Individuals with the correct HLA haplotype can generate TCRs that specifically 
recognize HLA-E complexes presenting hCMV UL40-derived peptides (VMAPRTLIL, (20)).  
Comparison of our structure with the complex crystal structure of one such TCR, KK50.4, bound 
to HLA-E demonstrates that the KK50.4 and NKG2A/CD94 footprints on HLA-E are essentially 
overlapping surfaces (Figure 3D, (21)).  CD94Q112 and KK50.4 residues βR98 and αΝ97 contact 
the peptide in comparable ways, intercalating between the side-chains of P5Arg and P8Phe and 
contacting the main-chain of P6Thr (Figure 3B).  NKG2A/CD94 buries more surface area than 
KK50.4 (~2600 Å2 versus ~2150 Å2), and consistent with this, the affinity of NKG2A/CD94 for 
HLA-E is considerably higher (~1 µM vs 30 µM). 
Why does NKG2A/CD94 bind any given HLA-E/peptide complex with a ~six-fold 
higher affinity than NKG2C/CD94, given their high sequence identity (95%), different at only six 
positions (Figure 2)?  Three of these differences are in a loop (NKG2A residues 167-170) that 
forms a significant part of the interface with CD94 (Figure 2).  Residues of both NKG2A and 
CD94 adjacent to this interface make significant contacts with HLA-E/peptide: CD94 residues 
112-114 interact with both the peptide and α1 helix of HLA-E, and NKG2A residues P171 and 
S172 likely contact HLA-EH155 and the peptide at P5Arg.  In order to test whether residues 167-170 
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account for the difference in affinity between NKG2A/CD94 and NKG2C/CD94, we swapped 
these residues between NKG2A and NKG2C (generating “NKG2Ctriple” and “NKG2Atriple” 
variants) and tested the effect on affinity for two different HLA-E complexes by surface plasmon 
resonance (table 1).  The NKG2Ctriple/CD94 mutant bound HLA-E with nearly identical affinities 
as wtNKG2A/CD94, while the NKG2Atriple/CD94 mutant bound with affinities much more 
similar to wtNKG2C/CD94.  These results establish that NKG2x interface residue 167-170 
indeed account for the difference in affinity between NKG2A/CD94 and NKG2C/CD94.  
Comparable results have also been reported by a recent study (12).  
Because the NKG2x residues that account for the affinity difference form the interface 
with CD94 and do not appear to directly contact HLA-E/peptide, the affinity difference is likely 
due to adjustments in heterodimer orientation that indirectly alters interactions with HLA-E.  
Residues adjacent to the NKG2A-CD94 interface include NKG2AP171 and CD94Q112, both of 
which potentially contact peptide P5Arg.  This raised the possibility that the P5Arg also contributes 
to the affinity difference between NKG2A and NKG2C.  In order to test this, we generated HLA-
E presenting the HLA-G nonamer with P5 mutated to Lys (VMAPKTLFL) and measured the 
binding affinity to NKG2A/CD94 and NKG2C/CD94.  The affinities for both receptors were very 
similar (10 µM for NKG2A/CD94 and 12 µM for NKG2C/CD94, table 1), confirming the 
importance of P5Arg in contributing both to the overall affinity as well as the affinity differential 
between NK2A/CD94 and NKG2C/CD94.  
Many immune receptors are targeted for immune evasion by viral and bacterial decoy 
ligands or mimetics and may be adaptively evolving in order to avoid such interactions.  In this 
scenario, the immune receptors would be evolving under positive selection, meaning that non-
synonymous, or sequence-altering, changes would be favored.  To look for signatures of positive 
selection in the NKG2A and NKG2C genes, we analyzed gene sequences from primate species 
spanning over 35 million years of evolution and found that the sequence data for both genes fit a 
codon model that permits positive selection (Nsites model M7; p=0.002 for NKG2A, p=0.006 for 
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NKG2C).  This indicates that both NKG2A and NKG2C have evolved under positive selection, 
suggesting that both genes have been actively engaged in a host-pathogen conflict throughout 
primate evolution.  In contrast, a similar evolutionary analysis of CD94 in primates did not reveal 
any evidence of positive selection.  The identification of specific amino acid residues in NKG2A 
and NKG2C that are evolving under recurrent positive selection can implicate the amino acid 
residues or domains that are directly interacting with the pathogen-derived protein.  Under two 
different methods (the NSsites models and REL analysis), we identified two NKG2A and two 
NKG2C ectodomain codons as having repeatedly evolved under positive selection (Figure 4A): 
NKG2AI168 (0.9998, 283); NKG2AP171 (0.99, not identified); NKG2CS166 (0.95, 446); and 
NKG2CK195 (0.95, 329); where the numbers in parentheses correspond to the individual 
probabilities, BEB posterior probability, from NSsites (22), and Bayes factor, from REL, (23), 
respectively. All codons listed had a posterior probability >95% in NSsites.  These results are 
particularly intriguing because NKG2AI168, NKG2AP171 and NKG2CS166 lie at the interface with 
CD94 and are critical to determining the overall affinity of the interaction with HLA-E.  NKG2C 
codon 195, on the other hand, is distant from the HLA-E interacting surface. 
Because of the strong signals of positive selection in HLA-E interacting residues, we 
hypothesized that NKG2x/CD94 receptors may also be interacting with a pathogen-derived 
ligand.  Potential candidates included two MHC-related CMV proteins, gpUL142 and gpUL18.  
gpUL18, which like class I MHC associates with β2-microglobulin (β2m) and peptide, binds with 
very high affinity (KD in the low nM range) to the inhibitory NK receptor LIR1/ILT2/CD85j (24, 
25). Several recent studies, while circumstantial, have suggested the possibility of direct 
interactions between NKG2C/CD94 and CMV-encoded proteins, including gpUL18 (26, 27).  In 
order to assess this possibility, surface plasmon resonance binding studies, in which glycosylated 
gpUL18 was chip-coupled, clearly demonstrate an interaction between NKG2C/CD94 and 
gpUL18, but not between NKG2A/CD94 and gpUL18 (Figure 4B).  While we cannot 
satisfactorily fit these data with appropriate binding models (possibly due to heterogeneity in this 
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preparation of the heavily glycosylated gpUL18 protein), precluding quantitation, the interaction 
is likely to be weak, with a KD in the 10-100 µM range The use of the same gpUL18-coupled 
surface for both receptors provided an internal binding control.  This result confirms the 
possibility that NKG2x/CD94 receptors are under positive selection due to genetic conflict with 
pathogen-associated proteins. 
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Discussion 
Low resolution structures can be a rich source of information, providing valuable insight into 
biological questions (28).  Despite the low resolution of this analysis, the NKG2A/CD94–HLA-E 
complex structure reveals important details about the recognition mechanism of this important 
family of immunoreceptors, accounting both for affinity differences between NKG2A and 
NKG2C for HLA-E and between different peptides for NKG2x receptors.  Sequence differences 
in NKG2x residues 167-170, which form part of the heterodimer interface, account for the 
affinity difference between NKG2A/CD94 and NKG2C/CD94 for given HLA-E/peptide 
complexes. While a crystal structure of NKG2C/CD94 is not yet available for comparison, we 
hypothesize that these interface residues indirectly affect ligand affinity through changes in the 
overall arrangement of domains in NKG2x/CD94 receptors.  In order for this mechanism to 
explain observed affinity differences, NKG2x/CD94 receptors should be relatively rigid, unlike 
NKG2D homodimers, which show significant interface flexibility (29, 30).  The near-perfect 
superimposibility of the ligand-bound and free states of NKG2A/CD94 supports such a 
conclusion.  Studies of the murine C-type lectin-like Ly49 family of receptors, which function as 
homodimers in binding to MHC ligands, have also demonstrated that residues at the homodimer 
interface critically affect ligand binding (31-33). 
 Our comparative analysis across primate species revealed that both NKG2A and NKG2C 
are evolving under strong positive selection, consistent with involvement in a host-pathogen 
conflict.  We note that this is not the only possible explanation of the data.  However, residues 
encoded by codons with the highest signal for positive selection either lie in or near the HLA-E 
binding surface or in the NKG2x/CD94 interface (with the exception of NKG2CK195), positions 
that may affect ligand interactions directly or indirectly.  In support of the host-pathogen conflict 
hypothesis, direct binding studies do show a specific, though weak, interaction between a likely 
extant candidate, hCMV gpUL18 and NKG2C/CD94, though not between NKG2A/CD94 and 
gpUL18.  The nature of this interaction suggests that NKG2x/CD94 receptors may directly 
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interact with virally-encoded proteins, possibly hCMV gpUL18 or related proteins, either as part 
of a viral immunoevasion strategy, usurping the inhibitory receptor NKG2A/CD94 as gpUL18 
appears to subvert LIR1, or as an immune system response to such an evasion strategy, by 
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• Materials and Methods 
Protein expression & purification: Human NKG2A (residues 99 to 233 plus an N-terminal 6xHis 
tag) and CD94 (residues 31-179) were both expressed and purified as previously described (4).  
Mutations in NKG2A and NKG2C were introduced using the QuikChange procedure 
(Stratagene).  For crystallography, NKG2A/CD94 was additionally digested overnight at room 
temperature with bromelain (Calbiochem) at a ratio of 30:1.  The HLA-E complex, containing a 
nonamer peptide derived from the leader sequence of HLA-G (VMAPRTLFL), was refolded by 
dilution as previously described (10) and purified by size exclusion and ion exchange 
chromatography to separate complexes from free heavy chains.  For the final step of purification, 
NKG2A/CD94 and HLA-E were co-purified by size exclusion chromatography. 
Crystallography: NKG2A/CD94–HLA-E complex was concentrated to 4.0 mg/mL and 
crystallized by hanging drop vapor diffusion at 18°C by mixing equivalent volumes of protein 
solution and reservoir buffer (1.8 M (NH4)2SO4, 0.3-0.7% sucrose, 100 mM Tris (pH 8.0)), with 
crystals typically forming after two to four weeks.  Crystals were dehydrated by transferring the 
coverslip to a well containing 3.0 M (NH4)2SO4 and 100 mM Tris (pH 8.0) overnight and were 
cryopreserved in well solution plus 25% sucrose w/w in liquid nitrogen.   
X-ray data were collected at the Advanced Light Source (Berkeley, California), beamline 
8.2.2, and were processed with DENZO/Scalepack; phases were determined by molecular 
replacement using AMoRe, as implemented in the CCP4 suite of programs (34), with HLA-E 
(1KPR.pdb) and a CD94 monomer (1B6E.pdb) as independent search models.  Initial phases 
were improved using the density modification program DM (CCP4 suite).  A homology model of 
NKG2A based on the structure of CD94 was placed into the electron density manually using 
COOT (35) and rebuilt according to the electron density.  When submitted to the DALI server 
(36), this partially built NKG2A identified DC-SIGN (1SL6.pdb) as the closest structural 
homolog of NKG2A.  DC-SIGN was then used as a reference molecule to complete the first 
NKG2A molecule.  This first NKG2A/CD94 complex was docked onto the second HLA-E 
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molecule, creating our first model for the entire AU, encompassing two complete complexes. A 
TLS restrained refinement was performed, which improved Rwork to 0.34 and Rfree to 0.38.  We 
completed our model with minimal manual building into regions where density was unequivocal.  
Our completed refined structure showed an overall R value of 0.33 and Rfree of 0.37.  Recently the 
structure of NKG2A/CD94 by itself was published (3BDW.pdb).  We carried a further round of 
rigid body refinement using the NKG2A coordinates from this structure, with a final R value of 
32.2 and Rfree of 35.5.  NCS restraints were imposed throughout refinement. 
Our initial solvent-flattened map, which was unbiased with respect to NKG2A, showed 
structural features not easily predicted from sequence analysis alone.  We attempted to use CD94 
and NKG2D, the two closest matches in terms of sequence identity, to generate our initial 
NKG2A model.  However, based on a DALI search the electron density of NKG2A more closely 
resembled DC-SIGN, CD69 and tetranectin, all lectin or lectin-like proteins with lower sequence 
identity to NKG2A, most likely due to the 2nd α-helix present in these molecules but not CD94.  
The moderately high crystallographic R-factors of our final model are likely due to a combined 
effect of the low resolution of the crystal and its high intrinsic disorder.  We have tabulated 
statistics for the 32 structures deposited in the PDB within the last five years that have resolution 
in the range of 3.9-4.1Å.  The average Rfree for these structures is 0.35 and average Rwork is 0.32 
(medians are 0.35/0.31).  The Rfree ranges from 0.25-0.50, and the Rwork ranges from 0.20-0.49, 
showing that our model is comparable in quality to the standard in this resolution range.   
Interaction analysis: Surface plasmon resonance (SPR) measurements were carried out on 
Biacore3000 instrumentation.  All proteins used for SPR were repurified by SEC in HBS-EA 
buffer (Biacore AB) within 48 h of use.  Protein concentrations were determined by bicinchoninic 
acid protein assay (Pierce), with associated errors ≤2%.  Affinity interactions between 
NKG2x/CD94 and HLA-E were carried out as described (4).  To assess the gpUL18-
NKG2x/CD94 interaction, ~1000 response units gpUL18 (the kind gift of Pamela Bjorkman) was 
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amine coupled to a CM sensor chip as described (24); NKG2A/CD94 and NKG2C/CD94 were 
used as analytes.  
Evolutionary analysis: Multiple sequence alignments for NKG2A and NKG2C for available 
primate sequences were generated with Clustal_X (37).  Accession numbers for primate NKG2A 
genes include: (H. sapiens, AF461812), (P. troglodytes, AF350005), (M. mulatta, AF190979), M. 
fasicularis, AJ585528), (Papio anubis, EF426674), (P. pygmaeus, AF470391), (C. jacchus, 
EF050432), (S. sciureus, EU024495); Accession numbers for primate NKG2C genes include: (H. 
sapiens, AJ001684), (P. troglodytes, AF259057), (M. mulatta, AJ585531), (M. fasicularis, 
AJ585530), (C. jacchus, EF050434), (S. sciureus, EU024496).  Additional primate sequences for 
the NKG2C gene were obtained by performing BLAST inquiries of the Trace Archives for G. 
gorilla, P. hamadryas and P. pygmaeus abelii.  A maximum likelihood analysis was performed 
with codeml from the PAML 3.14 software package (22).  To detect the selective pressures 
shaping the evolution of each gene, the multiple alignments were fit to an NSsites model that 
allowed positive selection (M8) or disallowed positive selection (M7), assuming the F3X4 model 
of codon frequencies.  Likelihood ratio tests were performed to determine whether allowing the 
codons to evolve under positive selection would give a significantly better fit for the data.  To 
identify specific codons that have undergone recurrent positive selection, we used the NSsites 
model in codeml from the PAML 3.14 software (22). To confirm the sites identified by the 
NSsites approach, we also used the random effects method (REL) from the web-based 





Figure 1.  The NKG2A/CD94/HLA-E complex structure.  Ribbon representations of the complex 
viewed from the side (A) or from above (B), colored by chain (NKG2A: red; CD94: green; HLA-
E heavy chain: blue; β2m: purple; peptide (showing all atoms): yellow).  (C)  Superpositions of α-
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carbon backbone traces of NKG2A/CD94 crystallized in complex with HLA-E (showing the de 
novo-built NKG2A model; NKG2A: dark green; CD94: dark red) and alone (NKG2A: pale 
green; CD94: pale red; Sullivan et al., 2007).  The superpositions were aligned on CD94.  Note 
that the structure of the receptor in the complex includes residues 200-203 that are absent from 
the free structure.  (D) A schematic representation of the contacts between NKG2A (red 
spheres)/CD94 (green spheres) and HLA-E α1 (light blue) and α2 (dark blue) domains.  An 
asterisk indicates residues (HLA-ER65, HLA-ER79, HLA-EE166, NKG2AR215) predicted to be 
involved in binding by mutagenesis (Sullivan et al., 2007) but are not contacts in the structure. 
 
Figure 2. Sequence alignment of human NKG2x receptors.  NKG2A secondary structural 
elements from the complex (red) and free (black) structures are shown above the sequences (β-
sheets: arrows; α-helices as wavy lines); CD94 secondary structure elements from the complex 
(green), NKG2A/CD94 free (3BDW, black) and CD94 alone structures (1BSE, orange) are 
shown below.  Additionally, CD94 residues that bind HLA-E/peptide are indicated by green 
triangles; NKG2A residues that bind HLA-E/peptide by red triangles; CD94 residues contacting 
NKG2A by magenta rectangles; and CD94 residues contacting NKG2A by cyan rectangles.  
Residues in the alignments shaded blue highlight sequence differences between NKG2A and 
NKG2C.  Paired cysteine residues in NKG2A that form intrachain disulfide bonds are numbered 
above the alignments from one to three. 
 
Figure 3: Contacts between NKG2A/CD94 and HLA-E/peptide. (A) Molecular surface 
representations are shown of NKG2A (red), CD94 (green) and HLA-E (blue), with the peptide 
shown in an all-atom representation (N-terminus on the left).  The complex has been splayed 
open to reveal the interface, with regions on each half of the complex colored by the molecule 
making reciprocal contacts.  Coils have been included on the right to indicate the position of the 
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HLA-E α-helices from the complex relative to NKG2A/CD94.  (B) Contacts between 
NKG2A/CD94 (left) or TCR KK50.4 (right) and HLA-E are shown, with the molecules shown as 
ribbons, colored as in (A).  The TCR α chain is purple, and the TCR β chain is green.  (C) The 
complex is shown as in (A), but with interface residues colored by a heat map (mutations with 
>10-fold effect on affinity: red for HLA-E or salmon for CD94; three- to five-fold effect: yellow; 
two-fold or less: blue) based on the previous alanine mutagenesis analysis (Sullivan et al., 2007).  
(D) Schematic representation of the binding footprints of NKG2A/CD94 (yellow) and TCR 
KK50.4 (blue) on HLA-E.   
 
Figure 4:  NKG2C/CD94 binds to hCMV gpUL18. (A) Residues in NKG2A (Pro171), NKG2C 
(Lys195) or both (NKG2AI168/NKG2CS166, positions that are equivalent in the alignment, 
indicated by an *) evolving under positive selection (i.e with PAML scores of >0.95) are mapped 
onto the structure of NKG2A (red), shown in a ribbon representation.  (B) SPR sensorgrams of 
the response of NKG2A/CD94 (top) and NKG2C/CD94 (bottom) analytes to chip-coupled 
gpUL18.  Concentrations of NKG2A/CD94 are 1.6, 3.1, 6.3, 12.5 and 25.0 µM; concentrations of 
NKG2C/CD94 are 1.25, 2.5, 5, 10, 20 and 40 µM.  Injection start and stop points are marked by 
arrows. 
 
Supplementary Figure 1: Electron density from the original density modified (dm1) map of the 
α2 helix of NKG2A (red) and CD94 (green) contoured at 1.5 sigma. 
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KD’s in µM of NKG2A/C mutants.  
 HLA-E*G (a) HLA-E*b27(b) HLA-E*Kpeptide (c) 
wtNKG2A 0.8 ± 0.055 5.7 ± 0.4 12.4 ±1.5 
wtNKG2C 5.2 ± 0.2 18.2 ±0.5 10.6 ±1.2 
NKG2C(165-168 SIIS) 0.9 ± 0.1 3.8 ± 0.1  
NKG2A(167-170 ASIL) 3.8 ± 0.3 12.9 ±2.8  
a:  peptide sequence is VMAPRTLFL;  
b:  peptide sequence is VTAPRTLLL; 
c:  peptide sequence is VMAPKTLFL 
 
